Meeting
2023 ASCO Genitourinary Cancers Symposium
Metastasis-directed ablative radiotherapy in castrate-resistant oligometastatic prostate cancer: A retrospective study of 8 high-volume French centers from the COLib (Cercle des Oncologues Libéraux).
Authors
Jerome Chamois
Institut de Cancérologie et Radiothérapie Bretillien ICRB, Saint Gregoire, France
Jerome Chamois , Anne-Lise Septans , Benjamin Schipman , Emmanuel Gross , Nicolas Blanchard , Victor Passerat , Christophe Debelleix , Charles Gaetan Hemery , Igor Latorzeff , Yoann Pointreau
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Therapeutics
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 152)
DOI
10.1200/JCO.2023.41.6_suppl.152
Abstract #
152
Poster Bd #
E12
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Prostate-specific membrane antigen PET response associates with radiographic progression-free survival following stereotactic ablative radiation therapy in oligometastatic castration-sensitive prostate cancer.
First Author: Philip Sutera
Poster
2022 ASCO Annual Meeting
Focal radiation with pulsed systemic therapy of abiraterone, androgen deprivation therapy (ADT), olaparib towards castration-sensitive oligometastatic prostate cancer (FAALCON Trial).
First Author: Zachery R Reichert
Poster
2020 Genitourinary Cancers Symposium
A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE).
First Author: Phuoc T. Tran
Poster
2017 ASCO Annual Meeting
Stereotactic ablative radiation therapy for the treatment of oligometastatic prostate cancer.
First Author: Phuoc T. Tran